ArticleJTO clinical and research reports2026

Patient-Reported Symptoms and Quality of Life With Sacituzumab Govitecan Versus Docetaxel in Metastatic NSCLC: The Phase 3, Randomized EVOKE-01 Trial.

Niels Reinmuth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.